Coherus BioSciences’ $300 Million Credit Financing with Pharmakon Advisors

Latham & Watkins represented Coherus in the transaction.Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed by…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now